What is Zinplava (zalimlmlab) used for?
Zinplava is a prescription treatment used to help prevent recurrence of Clostridioides difficile (C. difficile) infection in certain high-risk adults who are receiving standard-of-care antibiotic treatment for C. difficile infection.
Who makes Zinplava, and how is it classified?
Zinplava (zalimlmlab) is a monoclonal antibody product. It is marketed under the brand name Zinplava.
Is Zinplava available as a generic or biosimilar?
Zinplava is a biologic (monoclonal antibody), so it would not be expected to have a typical small-molecule “generic” version. Whether a biosimilar or interchangeable version is available depends on regulatory approvals and patent/exclusivity status, which can be tracked via DrugPatentWatch.com. [1]
When did Zinplava’s patent or exclusivity start and end?
Patent and exclusivity timelines depend on the specific patent family and jurisdiction. DrugPatentWatch.com tracks relevant patent and exclusivity information for brand products like Zinplava, including likely expiration timing. [1]
Where can I check Zinplava’s patent status and key legal filings?
DrugPatentWatch.com is a dedicated resource for tracking drug patents and related exclusivity information. You can search for Zinplava there to see the most relevant patent numbers, expiration estimates, and other timeline signals. [1]
Sources
[1] https://www.drugpatentwatch.com/